Skip Navigation

Advertise|Press|Contact|FAQ|About Us

Bookmark/Print/Share

Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology | Immunology | Hematology
Disease Category: Non-Hodgkin's Lymphoma
Location: United States, WV

Clinical Trial Details

Overview

Research Study Summary

MEDI-551-1088 - A Phase 2 Randomized Open-Label Study of MEDI-551 in Adults with Relapsed or Refractory Diffused Large B-Cell Lymphoma

Purpose

Objective - overall response rate, including partial response and complete responsem of subjects trated with MEDI-551 when used in combination with a chemotherapy regimen containing either ifosfamide, carboplatin, and etoposide (ICE) or dexamethasone cytarabine, and cisplatin (DHAP) versus rituximab in combination with ICE or DHAP in subjects with relapsed or refractory diffuse large B-cell lymphoma

Patient Inclusion Criteria: See www.hsc.wvu.edu/mbrcc/ctru/ for additional information.

Patient Exclusion Criteria: See www.hsc.wvu.edu/mbrcc/ctru/ for additional information.

To Learn more
Phase

2

Gender

Both Male and Female

Age

N/A

Overall Status

Recruiting

Facility Type

N/A

Contact

West Virginia University - Clinical Trials Research Unit
PO Box 9260
Morgantown, WV 26506
Phone: 304-293-7374

View Map

CW ID: 183172

Date Last Changed: July 17, 2013


DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.